Data and trends from the ECDC Annual Epidemiological reports for 2016 on:
Chlamydia (http://bit.ly/AERch16)
Lymphogranuloma venereum (http://bit.ly/AERLGV16)
Gonorrhoea (http://bit.ly/AERsy16)
Syphilis (http://bit.ly/AERsy16)
Congenital syphilis (http://bit.ly/AERcs16)
See also: https://ecdc.europa.eu/en/annual-epidemiological-reports
What is the current situation of HIV in Europe and Central Asia?
How can we more effectively prevent new infections?
Presentation by Anastasia Pharris,
European Centre for Disease Prevention and Control (ECDC)
at Glasgow HIV Drug Therapy Conference
28 October 2018
ECDC symposium "Responding to two of the main STI threats of our time: syphilis and antimicrobial resistant Neisseria gonorrhoeae"
Presentation by: Otilia Mårdh
Presented at: IUSTI 2019, Tallinn
Presentation at European Harm Reduction Conference
Bucharest, 21 November 2018
Author Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)
Presentation during the 17th European AIDS Conference (EACS) 2019 looking at the status of HIV pre-exposure prophylaxis PrEP in Europe..
Presenter: Teymur Noori, European Centre for Disease Prevention and Control (ECDC)
Presentation from the opening session of the 17th European AIDS Conference (EACS) 2019, Basel, Switzerland.
Presenter: Anastasia Pharris, European Centre for Disease Prevention and Control.
Summary slides on the epidemiological situation in the EU/EEA.
2018 surveillance data.
Report and ppt slides available from: http://bit.ly/HIVAIDSsurv18
What is the current situation of HIV in Europe and Central Asia?
How can we more effectively prevent new infections?
Presentation by Anastasia Pharris,
European Centre for Disease Prevention and Control (ECDC)
at Glasgow HIV Drug Therapy Conference
28 October 2018
ECDC symposium "Responding to two of the main STI threats of our time: syphilis and antimicrobial resistant Neisseria gonorrhoeae"
Presentation by: Otilia Mårdh
Presented at: IUSTI 2019, Tallinn
Presentation at European Harm Reduction Conference
Bucharest, 21 November 2018
Author Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)
Presentation during the 17th European AIDS Conference (EACS) 2019 looking at the status of HIV pre-exposure prophylaxis PrEP in Europe..
Presenter: Teymur Noori, European Centre for Disease Prevention and Control (ECDC)
Presentation from the opening session of the 17th European AIDS Conference (EACS) 2019, Basel, Switzerland.
Presenter: Anastasia Pharris, European Centre for Disease Prevention and Control.
Summary slides on the epidemiological situation in the EU/EEA.
2018 surveillance data.
Report and ppt slides available from: http://bit.ly/HIVAIDSsurv18
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level.
This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
Any questions? Contact press@ecdc.europa.eu
Providing an overview on data, trends and summary of findings on the hepatitis B and C surveillance data from EU/EEA countries for the year 2017:
Find ECDC's Annual Epidemiological reports online: http://bit.ly/ECDCAER
This presentation summarises the main data from the ECDC Annual epidemiological reports 2017 on chlamydia, gonorrhoea, lymphogranuloma venereum, (congenital) syphilis
ECDC poster at the 16th European AIDS Conference, 2017, Milan.
Authors: Lara Tavoschi, Joana Gomes-Dias, Anastasia Pharris, the EU/EEA HIV Surveillance Network
Shigellosis outbreaks associated with sexual transmission among men who have sex with men (MSM) have been reported in recent years from the United Kingdom, Germany and Spain, with severe infections among HIV-positive MSM.
Poster at ESCAIDE conference 2016, Stockholm.
Teymur Noori, ECDC
22nd International AIDS Conference, Amsterdam 2018
2018 European African HIV/AIDS & Hepatitis C Community Summit. "Our Voices Matter for a lasting solution!!"
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2015, almost 30 000 people were diagnosed in European Union and European Economic Area Member States; a rate of 6.3 cases in every 100 000 people (when adjusted for reporting delay).
This report, prepared jointly with the WHO Regional Office for Europe, presents data on HIV and AIDS for the whole European Region, including the EU and EEA countries. Analyses are provided for the EU and EEA region.
Presentation on epi data during the conference "New challenges and unmet needs of children and adolescents living and ageing with HIV/AIDS", 19-22 January 2017, Bucharest, Romania
Data and trends on hepatitis B and C for the countries of the European Union and European Economic Area.
2015 data.
See also ECDC's Annual Epidemiological Report: https://ecdc.europa.eu/en/annual-epidemiological-reports
Based on ECDC surveillance report on Sexually transmitted infections in Europe 2013, these slides describes the epidemiological features and basic trends of the five STI under EU surveillance: chlamydia trachomatis infection, gonorrhoea, syphilis, congenital syphilis, and lymphogranuloma venereum. It covers the years 2004 to 2013.
HIV transmission remains a major public health concern and affects more than 2 million people in the WHO European Region.
These ECDC slides summarise findings from the report which is available via http://bit.ly/WAD_18
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2014, almost 30 000 people were diagnosed in European Union and European Economic Area Member States. This slide set includes maps, graphs and tables from the 2014 HIV/AIDS surveillance report, published jointly by ECDC and WHO Europe.
Presentation by ECDC HIV expert Anastasia Pharris on epidemiological challenges for the HIV response in Europe.
Presented at: 16th European AIDS Conference, 26 October 2017, Milan.
In 2014, over 57 000 new cases of hepatitis B and C were reported. 22 442 cases of hepatitis B virus infection were reported in 30 EU/EEA Member States and 35 321 cases of hepatitis C were reported from 28 EU/EEA Member States.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation: ECDC Acting Director Dr Andrea Ammon.
a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level.
This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
Any questions? Contact press@ecdc.europa.eu
Providing an overview on data, trends and summary of findings on the hepatitis B and C surveillance data from EU/EEA countries for the year 2017:
Find ECDC's Annual Epidemiological reports online: http://bit.ly/ECDCAER
This presentation summarises the main data from the ECDC Annual epidemiological reports 2017 on chlamydia, gonorrhoea, lymphogranuloma venereum, (congenital) syphilis
ECDC poster at the 16th European AIDS Conference, 2017, Milan.
Authors: Lara Tavoschi, Joana Gomes-Dias, Anastasia Pharris, the EU/EEA HIV Surveillance Network
Shigellosis outbreaks associated with sexual transmission among men who have sex with men (MSM) have been reported in recent years from the United Kingdom, Germany and Spain, with severe infections among HIV-positive MSM.
Poster at ESCAIDE conference 2016, Stockholm.
Teymur Noori, ECDC
22nd International AIDS Conference, Amsterdam 2018
2018 European African HIV/AIDS & Hepatitis C Community Summit. "Our Voices Matter for a lasting solution!!"
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2015, almost 30 000 people were diagnosed in European Union and European Economic Area Member States; a rate of 6.3 cases in every 100 000 people (when adjusted for reporting delay).
This report, prepared jointly with the WHO Regional Office for Europe, presents data on HIV and AIDS for the whole European Region, including the EU and EEA countries. Analyses are provided for the EU and EEA region.
Presentation on epi data during the conference "New challenges and unmet needs of children and adolescents living and ageing with HIV/AIDS", 19-22 January 2017, Bucharest, Romania
Data and trends on hepatitis B and C for the countries of the European Union and European Economic Area.
2015 data.
See also ECDC's Annual Epidemiological Report: https://ecdc.europa.eu/en/annual-epidemiological-reports
Based on ECDC surveillance report on Sexually transmitted infections in Europe 2013, these slides describes the epidemiological features and basic trends of the five STI under EU surveillance: chlamydia trachomatis infection, gonorrhoea, syphilis, congenital syphilis, and lymphogranuloma venereum. It covers the years 2004 to 2013.
HIV transmission remains a major public health concern and affects more than 2 million people in the WHO European Region.
These ECDC slides summarise findings from the report which is available via http://bit.ly/WAD_18
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2014, almost 30 000 people were diagnosed in European Union and European Economic Area Member States. This slide set includes maps, graphs and tables from the 2014 HIV/AIDS surveillance report, published jointly by ECDC and WHO Europe.
Presentation by ECDC HIV expert Anastasia Pharris on epidemiological challenges for the HIV response in Europe.
Presented at: 16th European AIDS Conference, 26 October 2017, Milan.
In 2014, over 57 000 new cases of hepatitis B and C were reported. 22 442 cases of hepatitis B virus infection were reported in 30 EU/EEA Member States and 35 321 cases of hepatitis C were reported from 28 EU/EEA Member States.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation: ECDC Acting Director Dr Andrea Ammon.
a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
ECDC presentation at the 15th Conference of the International Society of Travel Medicine, 15 May 2017.
Presenter: Teymur Noori
Questions?
Contact info@ecdc.europa.eu
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Marieke J. van der Werf and Csaba Ködmön, European Centre for Disease Prevention and Control, ECDC.
Despite notable progress in the past decade, tuberculosis (TB) is still a public health concern in many countries across Europe. The high rates of TB and multidrug-resistant TB outside the European Union/European Economic Area (EU/EEA) are of particular concern, as are the significant number of TB cases among vulnerable populations within the EU/EEA.
During the first 2 months of 2017 we have seen 1524 cases of measles reported from 14 EU/EEA countries. Measles does not only affect children but also older age groups. In 2014 over half of the cases were in adults over 20 years old, in 2015 and 2016 this age group accounted for approximately one third of all cases. Closing immunisation gaps in adolescents and adults who have not received vaccination in the past as well as strengthening routine childhood immunisation programmes will be vital to prevent future outbreaks and reach the elimination goal.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Masoud Dara, WHO Regional Office for Europe
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Summary of surveillance data for hepatitis B and hepatitis C across the European Union and European Economic area for 2016.
See also:
ECDC's Annual Epidemiological Report hepatitis B: http://bit.ly/AER16HBV
ECDC's Annual Epidemiological Report hepatitis C: http://bit.ly/AER16HCV
Surveillance data from 2013 show high numbers of newly diagnosed hepatitis B and C cases notified across Europe. Chronic cases dominate across both diseases with a marked variation between countries: in 2013, 19 930 cases of hepatitis B virus infection were reported in 28 EU/EEA Member States, a crude rate of 4.4 per 100 000 population. 26 EU/ EEA Member States recorded 32 512 cases of hepatitis C resulting in a crude rate of 9.9 per 100 000 population.
An overview on how European countries have been responding to the HIV epidemic since 2004 based on the commitments as outlined in the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia.
Presentation by: Erika Duffell, European Centre for Disease Prevention and Control, Stockholm, Sweden
Presentad at: International Liver Congress, April 2018
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Adam Bourne1, Beatrice Alba1, Alex Garner2, Gianfranco Spiteri3, Anastasia Pharris3, Teymur Noori3
1. Australian Research Centre in Sex, Health & Society, La Trobe University, Melbourne, Australia; 2. Hornet Gay Social Network, California, USA; 3. European Centre for Disease Prevention and Control, ECDC, Sweden
Presentation by Daniel Simões, HIV in Europe, Portugal , at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Jens Lundgren, Rigshospitalet, University of Copenhagen - European AIDS Clinical Society, Denmark, at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Chloe Orkin, Royal London Hospital - BHIVA, United Kingdom, at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Teymur Noori, ECDC, at AIDS 2018 conference during teh joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
2. Chlamydia
• In 2016, 403 807 cases of chlamydia infection were
reported in 26 EU/EEA Member States.
• The overall notification rate was 184 per 100 000 persons.
• Notification rates of chlamydia infection varied considerably
across Europe, with the highest country-specific rates more
than 5 000 times the country with the lowest rates. This is
mainly a reflection of the differences in chlamydia testing
and case finding rather than real differences in chlamydia
prevalence.
• Notification rates continue to be highest among young adult
women and heterosexuals.
• The overall trend appears stable over recent years, both at
the European and at the country level.
Source: European Centre for Disease Prevention and Control. Chlamydia infection. In: ECDC. Annual Epidemiological Report for
2016. Stockholm: ECDC; 2018. Online: http://bit.ly/AERch16
3. Chlamydia male-to-female ratio,
25 EU/EEA countries, 2016
Source: European Centre for Disease Prevention and Control. Chlamydia infection. In: ECDC. Annual Epidemiological Report for
2016. Stockholm: ECDC; 2018. Online: http://bit.ly/AERch16
4. Chlamydia cases per 100 000 population,
by age group and gender, EU/EEA, 2016
Source: Country reports from Bulgaria, Croatia, Cyprus, Denmark, Estonia, Finland, Iceland, Ireland, Latvia,
Lithuania, Luxembourg, Malta, Norway, Portugal, Romania, Slovakia, Slovenia, Sweden and the United Kingdom.
Source: European Centre for Disease Prevention and Control. Chlamydia infection. In: ECDC. Annual Epidemiological Report for
2016. Stockholm: ECDC; 2018. Online: http://bit.ly/AERch16
5. Chlamydia infections by transmission category
and gender (n=60 274), EU/EEA, 2016
Data from countries reporting transmission category for more than 60% of cases: Hungary, Latvia, Lithuania,
Malta, the Netherlands, Portugal, Romania, Slovakia, Slovenia and Sweden
Source: European Centre for Disease Prevention and Control. Chlamydia infection. In: ECDC. Annual Epidemiological Report for
2016. Stockholm: ECDC; 2018. Online: http://bit.ly/AERch16
6. Confirmed chlamydia cases per 100 000
population by year, EU/EEA countries reporting
consistently, 2007−2016
Source: Country reports from Cyprus, Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Malta, Norway, Poland, Romania,
Slovakia, Slovenia, Sweden, and the United Kingdom.
Source: European Centre for Disease Prevention and Control. Chlamydia infection. In: ECDC. Annual Epidemiological Report for
2016. Stockholm: ECDC; 2018. Online: http://bit.ly/AERch16
7. Lymphogranuloma venereum (LGV)
• In 2016, LGV data were reported by 22 countries, out of
which 13 reported 2 043 cases.
• Three countries (France, the Netherlands and the United
Kingdom) accounted for 86% of notified cases.
• Almost all cases were reported among men who have sex
with men; in those cases with known HIV status, 70% were
HIV positive in 2016.
• The number of reported cases continued to increase with
15% more cases reported in 2016 compared to 2015.
• A number of countries have not reported LGV cases over the
years, suggesting significant underdiagnosis and
underreporting.
European Centre for Disease Prevention and Control. Lymphogranuloma venereum. In: ECDC. Annual epidemiological report for
2016. Stockholm: ECDC; 2018. Online: http://bit.ly/AERLGV16
8. Age distribution of confirmed LGV cases,
EU/EEA, 2016
European Centre for Disease Prevention and Control. Lymphogranuloma venereum. In: ECDC. Annual epidemiological report for
2016. Stockholm: ECDC; 2018. Online: http://bit.ly/AERLGV16
9. Confirmed LGV cases among the five EU/EEA
Member States reporting the largest number of
cases in 2016, 2007–2016
European Centre for Disease Prevention and Control. Lymphogranuloma venereum. In: ECDC. Annual epidemiological report for
2016. Stockholm: ECDC; 2018. Online: http://bit.ly/AERLGV16
10. Gonorrhoea
• 75 349 cases of gonorrhoea were reported by 27 EU/EEA
Member States for 2016.
• The overall notification rate was 18.8 cases per 100 000
population.
• Rates of reported gonorrhoea infection vary considerably
across Europe, with higher rates reported in northern
Europe.
• Men who have sex with men (MSM) accounted for almost
half of reported cases (46%) in 2016.
• The number of reported cases remained stable compared to
2015 reflecting fewer diagnoses in the United Kingdom but
increases in other countries.
European Centre for Disease Prevention and Control. Gonorrhoea. In: ECDC. Annual Epidemiological Report for 2016.
Stockholm: ECDC; 2018. Online: http://bit.ly/AERNG16
11. Rate of confirmed gonorrhoea cases per 100 000
population by country, EU/EEA, 2016
European Centre for Disease Prevention and Control. Gonorrhoea. In: ECDC. Annual Epidemiological Report for 2016.
Stockholm: ECDC; 2018. Online: http://bit.ly/AERNG16
12. Gonorrhoea male-to-female ratio
in 26 EU/EEA countries, 2016
European Centre for Disease Prevention and Control. Gonorrhoea. In: ECDC. Annual Epidemiological Report for 2016.
Stockholm: ECDC; 2018. Online: http://bit.ly/AERNG16
13. Rate of confirmed gonorrhoea cases per 100 000
population, by age and gender, EU/EEA, 2016
Source: Country reports from Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Iceland, Ireland, Italy, Latvia,
Lithuania, Luxembourg, Malta, Norway, Portugal, Romania, Slovakia, Slovenia, Sweden, and the United Kingdom.
European Centre for Disease Prevention and Control. Gonorrhoea. In: ECDC. Annual Epidemiological Report for 2016.
Stockholm: ECDC; 2018. Online: http://bit.ly/AERNG16
14. Percentage of gonorrhoea infections by
transmission category and gender (n=57 137),
EU/EEA, 2016
Data from countries reporting transmission category for more than 60% of cases: Czech Republic, Denmark, France, Hungary,
Latvia, Malta, the Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Sweden and the United Kingdom.
European Centre for Disease Prevention and Control. Gonorrhoea. In: ECDC. Annual Epidemiological Report for 2016.
Stockholm: ECDC; 2018. Online: http://bit.ly/AERNG16
15. Rate of confirmed gonorrhoea cases per 100 000 population
by year, EU/EEA countries reporting consistently,
2007−2016
Source: Country reports from Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Iceland, Ireland,
Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain (only total), Sweden, and
the United Kingdom.
European Centre for Disease Prevention and Control. Gonorrhoea. In: ECDC. Annual Epidemiological Report for 2016.
Stockholm: ECDC; 2018. Online: http://bit.ly/AERNG16
16. Number of confirmed gonorrhoea cases by gender,
transmission category and year, EU/EEA countries reporting
consistently, EU/EEA, 2008−2016
Source: Country reports from the Cyprus, the Czech Republic, Denmark, France, Latvia, Lithuania, Malta, the Netherlands,
Norway, Romania, Slovenia, Sweden and the United Kingdom.
European Centre for Disease Prevention and Control. Gonorrhoea. In: ECDC. Annual Epidemiological Report for 2016.
Stockholm: ECDC; 2018. Online: http://bit.ly/AERNG16
17. Syphilis
• In 2016, 29 365 syphilis cases were reported in 28 EU/EEA
Member States (data were not available from Austria, Greece and
Liechtenstein), at a rate of 6.1 per 100 000 population. Reported
syphilis rates were eight times higher in men than in women.
• The majority of cases were reported in people older than 25
years, with young people between 15 and 24 years of age
accounting for 13% of cases.
• Two-thirds (66%) of the syphilis cases with information on
transmission category were reported in men who have sex with
men (MSM).
• Trends since 2011 show that syphilis rates have been increasing,
particularly among men, mainly due to an increase among MSM.
• Rates among women increased slightly in 2016.
European Centre for Disease Prevention and Control. Syphilis. In: ECDC. Annual epidemiological report for 2016. Stockholm:
ECDC; 2018. Online: http://bit.ly/AERsy16
18. Rate of confirmed syphilis cases per 100 000
population by country, EU/EEA, 2016
European Centre for Disease Prevention and Control. Syphilis. In: ECDC. Annual epidemiological report for 2016. Stockholm:
ECDC; 2018. Online: http://bit.ly/AERsy16
20. Rate of confirmed syphilis cases per 100 000
population, by age and gender, EU/EEA, 2016
Source: Country reports from Cyprus, the Czech Republic, Denmark, Estonia, Finland, Iceland, Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, Norway, Portugal, Romania, Slovakia, Slovenia, Sweden, and the United Kingdom.
European Centre for Disease Prevention and Control. Syphilis. In: ECDC. Annual epidemiological report for 2016. Stockholm:
ECDC; 2018. Online: http://bit.ly/AERsy16
21. Percentage of syphilis infections by transmission
category and gender (n=21 275), EU/EEA, 2016
Data from countries reporting transmission category for more than 60% of cases: Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Latvia, Lithuania, Malta, the Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Sweden and
the United Kingdom.
European Centre for Disease Prevention and Control. Syphilis. In: ECDC. Annual epidemiological report for 2016. Stockholm:
ECDC; 2018. Online: http://bit.ly/AERsy16
22. Distribution of reported syphilis infection
stages, EU/EEA, 2016
Source: Country reports from the Czech Republic, Estonia, France, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta,
the Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Sweden and the United Kingdom.
European Centre for Disease Prevention and Control. Syphilis. In: ECDC. Annual epidemiological report for 2016. Stockholm:
ECDC; 2018. Online: http://bit.ly/AERsy16
23. Rate of confirmed syphilis cases per 100 000 population
by year, EU/EEA countries reporting consistently,
2007−2016
Source: Country reports from the Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Germany, Ireland, Italy, Latvia,
Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden and the United Kingdom.
European Centre for Disease Prevention and Control. Syphilis. In: ECDC. Annual epidemiological report for 2016. Stockholm:
ECDC; 2018. Online: http://bit.ly/AERsy16
24. Number of confirmed syphilis cases by gender,
transmission category and year, EU/EEA countries reporting
consistently, EU/EEA, 2010−2016
Source: Country reports from the Czech Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Ireland, Latvia, Lithuania,
Malta, the Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Sweden and the United Kingdom.
European Centre for Disease Prevention and Control. Syphilis. In: ECDC. Annual epidemiological report for 2016. Stockholm:
ECDC; 2018. Online: http://bit.ly/AERsy16
25. Change in number of reported confirmed
cases of gonorrhoea, syphilis and LGV,
EU/EEA, 2012-2016
Source: Countries reporting both in 2012 and 2016. Country reports from Belgium, Bulgaria (not LGV), Croatia, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Germany (syphilis only), Hungary, Iceland, Ireland, Italy (not LGV), Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland,
Portugal, Romania (not LGV), Slovakia (not LGV), Slovenia, Spain (not LGV), Sweden and the United Kingdom.
26. Congenital syphilis
• In 2016, 37 congenital syphilis cases were reported in 23 EU/EEA
Member States, at a crude rate of 1.1 cases per 100 000 live births.
• The trend for reported congenital syphilis cases has remained stable in
recent years, but some countries reported small increases compared
with 2015.
• It is suspected that there is significant underreporting: seven countries
did not contribute to the reporting of congenital syphilis, and a further
13 reported zero cases in 2016.
• The low rates of congenital syphilis and decreasing rates of reported
syphilis among women suggest that most Member States have
programmes that aim at the elimination of congenital syphilis. Better
indicator data are needed, however, to assess the effectiveness of
antenatal screening programmes in all EU/EEA countries.
European Centre for Disease Prevention and Control. Congenital syphilis. In: ECDC. Annual Epidemiological Report for 2016.
Stockholm: ECDC; 2018. Online: http://bit.ly/AERcs16
27. Number of confirmed congenital syphilis cases
per 100 000 live births; number of countries reporting congenital
syphilis data, by year, 25 EU/EEA countries, 2005–2015
Source: Country reports from Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Iceland,
Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, the
United Kingdom.
European Centre for Disease Prevention and Control. Congenital syphilis. In: ECDC. Annual Epidemiological Report for 2016.
Stockholm: ECDC; 2018. Online: http://bit.ly/AERcs16
Note: In 2008, the United Kingdom started including data from a screening programme targeted at 15–24-year-olds in England. This programme offers community-based testing services outside of STI clinics and resulted in a large increase of chlamydia diagnoses from 2008 onwards.